Gestational Diabetes Mellitus (GDM) is a significant health concern, affecting up to 14% of pregnancies worldwide. It not only poses immediate risks to the mother and fetus but also increases the long-term risk of type 2 diabetes and cardiovascular diseases. Hence, optimizing GDM management is crucial.
Early detection and diagnosis of GDM can significantly improve pregnancy outcomes. Universal screening for GDM at 24-28 weeks of gestation using oral glucose tolerance test is recommended. For high-risk women, early screening in the first trimester should be considered.
First-line management of GDM involves lifestyle modifications. A balanced diet rich in fiber and low in simple sugars, along with moderate-intensity exercise for at least 30 minutes a day, can help control blood glucose levels. Regular self-monitoring of blood glucose is also essential.
If lifestyle modifications are insufficient, pharmacological interventions may be required. Insulin therapy is the gold standard for GDM management. However, oral hypoglycemic agents like metformin and glyburide are gaining acceptance due to their convenience and cost-effectiveness.
Postpartum follow-up is vital as GDM increases the risk of developing type 2 diabetes later in life. An oral glucose tolerance test should be performed at 6-12 weeks postpartum. Thereafter, regular screening for diabetes is recommended.
Optimal management of GDM requires a multifaceted approach, including early detection, lifestyle modifications, pharmacological interventions, and postpartum follow-up. By adhering to these strategies, healthcare professionals can significantly improve maternal and fetal outcomes while reducing the long-term risk of type 2 diabetes and cardiovascular diseases.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation